Trade negotiations are nearing the finish line after nearly two decades of hard bargaining on both sides.

Weak currency, labour reforms and passenger compensation costs dragged Indigo's earnings.

By Jaspreet Kalra and Dharamraj Dhutia MUMBAI, Jan 23 (Reuters) - The Reserve Bank of India on Friday unveiled measures to ...

By Gilles Guillaume and Aditi Shah PARIS/NEW DELHI, Jan 23 (Reuters) - France's Renault is banking on the cult following of ...

India saw a 17% rise in the live events space in 2025, marking a boom in demand for experiences. This was led by Gen-Z and ...

Foreign investors have been selling out of India’s highly valued stockmarket. The rupee slid to a record low against the ...

Single-tusked male struck first on New Year’s Day when it killed a man, 35, in the village of Bandijhari in Jharkhand’s West ...

India and the UAE are aiming to double bilateral trade to $200 billion by 2032. On Monday, UAE president Sheikh Mohamed bin ...

By Gopika Gopakumar, Vibhuti Sharma and Ashwin Manikandan MUMBAI, Jan 23 (Reuters) - India's Axis Bank has put on hold plans ...

By Neha Arora and Aditya Kalra NEW DELHI, Jan 23 (Reuters) - Four major Indian steelmakers - Tata Steel, JSW Steel and ...

India will aim to extend its T20 dominance as the preparations for the World Cup will continue when they take on New Zealand ...

Jan 23 () - Sun ​Pharmaceutical ‌Industries, India's ‌top drugmaker by ⁠revenue, ‌said on Friday ‍that it has ​received ‌regulatory approval to manufacture and sell ⁠generic ​semaglutide ​in India.